menu
    • menu
    [{"orgOrder":0,"company":"Nika Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Agreement","leadProduct":"ITV-1","moa":"Human immunodeficiency virus Glycoprotein 41 (HIV gp41)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nika Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nika Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nika Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Nika Pharmaceuticals","sponsor":"Nika Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Vinpocetine","moa":"Phosphodiesterase 1 (PDE1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nika Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nika Pharmaceuticals \/ Nika Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Nika Pharmaceuticals \/ Nika Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Nika Pharmaceuticals

    Menu

    Nika Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nika Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Nika Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ITV-1

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Nika Pharmaceuticals, Inc. (NIKA) Signed a Distribution Agreement for Nigeria

                            Details : Nika Pharmaceuticals signed a distribution agreement for ITV-1 (ImmunH) in the Republic of Nigeria. ITV-1 is currently being evaluated for the treatment of HIV infections.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            July 18, 2024

                            Lead Product(s) : ITV-1

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nika Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Nika Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vinpocetine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Recipient : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Nika Pharmaceuticals Acquires Technologies for Three Drugs and One Supplement

                            Details : The acquisition includes technologies for producing generics as tablet, Vinpocetine, Menthyl Valerate, and Metamizole Sodium, and a dietary supplement, Tribulus Terrestris Herba Extractum Siccum.

                            Product Name : Vinpocetine-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 15, 2024

                            Lead Product(s) : Vinpocetine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth